INTRODUCTION
Bilirubin was recognized as a neurotoxin and the cause of kernicterus in the late 19th and early 20th centuries, 1 and research into the basic mechanism of bilirubin neurotoxicity began in earnest around 1950. Important issues in the first decades of basic bilirubin research included bilirubin binding and in vitro studies of toxicity. Bilirubin was found to inhibit a multitude of enzymes and to perturb membrane function, but inhibition of oxidative phosphorylation was thought by many to be the most likely candidate for a basic cellular mechanism of bilirubin toxicity (see Ref.
2 for a review). The question of what constitutes the basic mechanism for bilirubin neurotoxicity still remains open, and research continues. 3 Other issues include mechanisms of bilirubin entry into brain and its distribution in both brain regions and between brain intracellular compartments. The possible existence of a bilirubin-oxidizing enzyme in brain has also received attention.
A CANDIDATE-BASIC MECHANISM FOR BILIRUBIN NEUROTOXICITY
That bilirubin is toxic to so many biological reactions and systems suggested to us that if these reactions and systems had something in common, a reasonable working hypothesis might be that bilirubin in some way perturbed this common reaction or pathway. Protein/ peptide phosphorylation has been shown to be an important regulatory mechanism for many cell processes. A review of current knowledge regarding the many bilirubin-affected processes suggested that regulation by protein/peptide phosphorylation might constitute a common theme. In fact, one study documented an inhibitory effect of bilirubin on brain protein phosphorylation. 4 We subsequently showed that bilirubin inhibited phosphorylation of synapsin I, a protein which is preferentially localized to presynaptic vesicles. 5 As dephosphorylated synapsin I inhibits neurotransmitter release, this observation might explain why bilirubin inhibited synaptic activation in transverse rat hippocampal slices. 6 A further contribution to decreased synaptic function in the jaundiced brain might be the inhibitory interaction between bilirubin and transport proteins in synaptic vesicle membranes, leading to inhibition of neurotransmitter uptake into these vesicles. 7 We have also shown that bilirubin directly inhibits both exocytotic release and synaptic vesicular storage of brain catecholamines, and that this effect occurs independently of adenosine triphosphate and in the absence of a membrane potential. 8 These observations are compatible with the clinical observation of drowsiness in jaundiced infants, as well as the documented changes in brainstem auditory-evoked responses in such infants. Continued work in our laboratories showed that the inhibitory effect of bilirubin on synapsin I phosphorylation was not unique: a number of protein kinase interactions were similarly inhibited by bilirubin, suggesting that inhibition of protein/peptide phosphorylation could indeed be a basic mechanism for the effects of bilirubin in many biological systems. 9 Bilirubin is toxic in most biological systems tested. Several mechanisms have been suggested for this toxic effect, including inhibition of enzyme systems and inhibition of cell regulatory reactions ( protein / peptide phosphorylation ) . The identity of the basic mechanism ( s ) has not been conclusively proven, but inhibition of peptide phosphorylation, perhaps mediated or modulated by lysine at the active site ( s ) , appears to be compatible with many of the observations currently found in the literature. Bilirubin entry into brain is facilitated by drug displacement of bilirubin from its albumin binding, reduced albumin binding capacity, increased brain bloodflow, increased permeability of the blood -brain barrier, and other factors. The rate of bilirubin entry into brain, as well as the degree of retention and rate of clearance from brain, depends on which of these circumstances are operative. It is as yet unclear whether the mechanism responsible for increased brain bilirubin is important for toxicity. The mechanism for preferential localization of bilirubin to the basal ganglia in kernicterus is also not known. Bilirubin appears to distribute differentially to brain subcellular compartments and is oxidized in brain by an enzyme localized on the inner mitochondrial membrane. This enzyme is found both in neurons and in glia, but appears to be more active in the latter. The activity increases with postnatal age, and is subject to genetic variability in animals. The enzyme is cytochrome c -dependent. It is as yet not clear whether the activity of this enzyme serves a brain -protective effect in severe hyperbilirubinemia.
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Original Article
Bilirubin binds to albumin in serum, as well as to ligandin in hepatocytes. Lysine seems to be common to both binding sites. A review of the literature showed that lysine appeared to be a constituent of the active sites of many of the reactions perturbed by bilirubin, including the adenosine triphosphate binding subdomain II of the protein kinase family. We were able to show that lysinecontaining peptides could modulate the toxic effects of bilirubin on a model peptide-kinase system. 10 Thus, binding of bilirubin to lysine may play a role in the mediation and/or modulation of bilirubin neurotoxicity.
In summary, bilirubin has been shown to inhibit a wide range of phosphorylation reactions. Indirect evidence suggests that binding to lysine may play a role in these reactions. Given the key role of protein/peptide phosphorylation in the regulation of cell processes, widespread inhibition of such processes by bilirubin deserves consideration as a possible basic mechanism of bilirubin toxicity.
ENTRY, DISTRIBUTION, AND DISPOSITION OF BILIRUBIN IN BRAIN
Yellow staining of the basal ganglia of the brain in a jaundiced infant was described by Orth 11 in 1875. Three decades later, Schmorl 12 coined the term kernicterus to describe this particular pattern of staining. Schmorl autopsied a large number of neonates who had died with jaundice and found their brains to be jaundiced. However, only a small minority (5%) showed the pattern of staining, which he called kernicterus. Subsequent animal research has shown that bilirubin enters the brain in any individual with significant unconjugated hyperbilirubinemia. However, the pattern of distribution that characterizes kernicterus has been difficult to recreate experimentally. Thus, although many conditions that influence bilirubin entry into and clearance from brain have been studied, it is as yet not clear how bilirubin localizes preferentially to some regions of the brain in kernicterus, and to what extent this mechanism is connected to the occurrence of permanent brain damage. Although our understanding of these phenomena is still incomplete, it is important to keep the distinction between diffuse brain bilirubin staining and kernicterus in mind when reading reports about so-called ''low bilirubin kernicterus.'' Thus, although there is reason to believe that diffuse yellow staining of the brain may impact transiently on brain function, e.g., as recorded with brainstem auditory-evoked responses, 13 this diffuse staining pattern is not kernicterus, and it may not be associated with permanent sequelae. In a pathoanatomic sense, the term kernicterus should signify a characteristic regional staining pattern combined with evidence of neuronal loss/damage.
Previous work had shown that the unbound (''free'') bilirubin molecule can cross an intact blood-brain barrier. Opening of the blood-brain barrier and increased brain bloodflow are also associated with increased brain bilirubin concentrations (see Refs. 2, 3, 14 for reviews). Using the rat infusion model, we were not able to show that bilirubin distribution patterns in brain under conditions that increased the free bilirubin concentrations (drug displacement), opened the blood-brain barrier (hyperosmolality), or increased brain bloodflow (hypercapnia) corresponded to the pattern seen in kernicterus. 15 Subsequently, we attempted to separate what happens during the phase of acute entry of bilirubin into brain, 16 as well as the phase of bilirubin clearance from brain. 17 These studies also did not yield any clues to the mechanism of regional distribution seen in kernicterus. However, it does appear that the kinetics of increased brain bilirubin varies depending on the mechanism of entry. Thus, in hypercapnia, the acute entry of bilirubin into brain was significantly higher than in control conditions, while hyperosmolality did not significantly impact on the rate of entry relative to control animals. 18 Conversely, in hyperosmolality, the rate of bilirubin clearance from brain was significantly lower than in control and hypercapnic conditions. Thus, hypercapnia is associated with a rapid entry of bilirubin into brain, resulting in high brain bilirubin concentrations, but the rate of clearance is also rapid, resulting in a short duration of brain exposure to bilirubin. Opening of the blood-brain barrier by hyperosmolality, on the other hand, does not increase brain bilirubin acutely beyond what is seen in control conditions, but bilirubin is retained much longer in brain, resulting in prolonged exposure of the brain to bilirubin. At this time, it is not clear which is more important as far as neurotoxicity: brief exposure to high bilirubin concentrations, or prolonged exposure to more moderate concentrations.
We must assume that whatever the basic mechanism of bilirubin neurotoxicity is, the reaction or process affected by bilirubin must be localized to one (or more) subcellular compartment(s) of neurons. For bilirubin neurotoxicity to occur, bilirubin presumably must reach this particular neuronal subcellular compartment (or compartments). Using tritium-labeled bilirubin administered to young adult rats in vivo, we have recently attempted to trace bilirubin to subcellular compartments in brain. 19 To the best of our knowledge, this is the first published investigation of this nature.
Bilirubin was infused intravenously into young adult rats in vivo. After sacrifice, the brains were subjected to subcellular fractionation using gradient centrifugation in sucrose media. The bilirubin content of each fraction was measured with scintillation counting. When computed relative to the protein content of each fraction, there were significant differences between the brain subcellular fractions as far as bilirubin concentration. The bilirubin content was particularly high in the membrane fraction and in the final supernatant, which we have taken to represent cytoplasm. In contrast to the data from whole brain, in the subcellular fractions, hyperosmolality was associated with a particularly high concentration of bilirubin in animals sacrificed just 10 minutes after the infusion, representing acute entry in this set of experiments. The reasons for this difference are not intuitively obvious, but suggest the possibility that opening of the blood-brain barrier may present a particular risk for bilirubin encephalopathy, in that brain subcellular compartments are rapidly exposed to high concentrations of bilirubin, and brain exposure to bilirubin is prolonged due to delayed clearance. Indeed, animal experiments, which incorporated electroencephalographic measurements, suggested that opening of the blood-brain barrier was particularly potent as far as eliciting neurophysiologic evidence of bilirubin toxicity in jaundiced animals. 20 These data must be interpreted with caution. The fact, that relatively high concentrations of bilirubin were found in the membrane fraction, in no way proves that the documented effects of bilirubin on cell membrane function necessarily constitute the basic or even the most important toxic effect of bilirubin in cells. The use of a radioactive label to trace bilirubin intracellularly assumes that the label remains attached to bilirubin, and that the molecule is still bilirubin at the time of scintillation counting. Given the instability of tritium in aqueous media and the oxidation of bilirubin in brain cells (vide infra), none of those assumptions can be taken for granted. Our experiments were short term precisely to minimize such sources of error. However, we believe that the information presented may prove useful in planning in vitro experiments of bilirubin toxicity.
In other associated experiments, we have explored the putative roles of hemolysis and endotoxemia on bilirubin interaction with brain. 21, 22 Hemolysis neither affected the acute entry nor the rate of clearance of bilirubin from brain. If hemolysis, as most clinical guidelines assume, is associated with increased risk of bilirubin encephalopathy, the mechanism must involve other aspects than bilirubin accumulation in brain. Endotoxemia apparently affected the net accumulation of bilirubin in brain, but the brain/serum ratio of bilirubin was unaffected.
In summary, our studies have failed to demonstrate conditions resulting in a kernicteric pattern of bilirubin distribution in brain. The mechanism behind this phenomenon remains unknown. However, we have shown that the mode of bilirubin entry into brain has profound effects on the concentration, as well as retention, of bilirubin in brain. This may have an impact on toxicity.
BILIRUBIN OXIDATION IN BRAIN
The discovery that bilirubin may be oxidized in brain was due to the serendipitous observation by Brodersen and Bartels 23 that a jaundiced brain, which had been left unattended, lost its yellow color. Later, they showed that an enzyme localized on the inner mitochondrial membrane of several tissues, including the brain, was capable of oxidizing bilirubin. 23 The existence of this enzyme had subsequently been referred to in the literature, but was never verified by any other group, nor had it been further characterized.
In the 1990s, we studied this enzyme and verified the existence of a bilirubin-oxidizing enzyme on the inner mitochondria membrane of brain cells. 24 These studies were recently reviewed. 24 Briefly, the bilirubin-oxidizing activity appears to have the characteristics of an enzyme in that it is denaturable by heat and has definable pH and temperature maxima. The level of activity across several series of experiments, including different species and different strains of rats, has been in the range of oxidation at a rate of 100 to 300 pmol bilirubin per milligram of protein per minute.
The level of activity has been shown to be lower in the immature, compared to the adult, organism, and in mitochondria of a pure neuronal origin compared with mitochondria of mixed glial/ neuronal origin. If one assumes that oxidation of bilirubin in brain may serve a protective effect, these observations appear to be compatible with previous data, suggesting that the immature organism is more vulnerable to bilirubin toxicity and that neurons are more vulnerable than glia.
Studies of different rat strains have shown that the enzyme activity is subject to genetic variability. 25 The enzyme is cytochrome c-dependent, and is inhibited by some global inhibitors of cytochrome oxidases, including ketoconazole and clotrimazole, but not by inhibitors of monoamine oxidase or malate dehydrogenase, two other candidate oxidizing enzymes. Inhibition by cyanide as well as the azoles suggests that the enzyme in question is not identical to the commercially available bilirubin oxidase (EC 1.3.3.5), which is not affected by any of these agents.
The activity was not significantly affected by in vivo treatment with phenobarbital, hyperosmolality, endotoxemia, or sepsis. In vitro, the activity was reduced by eliminating oxygen from the reaction solution, but not by quenching free oxygen radicals. NAD, NADP, NADH, NADPH, GSH, or GSSH had no effect on the activity.
The existence of a bilirubin-oxidizing activity on the inner mitochondrial membrane of brain cells suggests the possibility that the brain may be able to protect itself against bilirubin toxicity. Further work will be required to verify this putative protective effect and to elucidate the circumstances, if any, under which bilirubin oxidation in brain may modulate bilirubin brain toxicity.
